TP53 and ovarian carcinoma: PRIMA-1Met reduced resistance to compound 25 and exhibited synergy effects in combination with compound 25 in p53-mutant and p53-wildtype ovarian cancer cells, accompanied by caspase activation, increased ROS formation, and reduced ATP.